SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, is pleased to announce that its CEO and co-founder, Dr. Chris Mansi, has been named an Innovator on the prestigious 2024 TIME100 AI list, an honor that recognizes the world’s 100 most influential people advancing and shaping artificial intelligence (AI)..

旧金山--（商业新闻短讯）--Viz.ai，人工智能驱动的疾病检测和智能护理协调的领导者，很高兴地宣布，其首席执行官兼联合创始人克里斯·曼西博士已被提名为著名的2024 TIME100人工智能名单上的创新者，这一荣誉表彰了世界上100位最有影响力的人，他们推动和塑造了人工智能（ai）。。

“It is an incredible honor to be included on the TIME100 AI list alongside such diverse and future-driven thinkers, but it is also a reflection of the collective efforts of our team at Viz.ai,” said Dr. Chris Mansi. “Since we started Viz.ai, we’ve been dedicated to advancing healthcare systems to work smarter and faster, and ultimately improve patient outcomes through artificial intelligence.

克里斯·曼西（ChrisMansi）博士说：“与这些多元化和未来驱动的思想家一起被列入Time 100 AI名单是一种莫大的荣誉，但这也反映了我们在Viz.AI团队的集体努力。”。“自从我们启动Viz.ai以来，我们一直致力于推动医疗保健系统更智能、更快地工作，并通过人工智能最终改善患者的预后。

We will continue to revolutionize the way patient care is delivered.”.

我们将继续彻底改变患者护理的方式。”。

As a trained neurosurgeon, Dr. Mansi is familiar with the challenges patients face in accessing treatments when they are needed. Inspired by a patient who underwent a successful brain surgery and yet died because the surgery came too late, Dr. Mansi founded Viz.ai in 2016 with a goal of using artificial intelligence to accelerate care coordination and reduce systemic delays that stand between patients and life-saving treatments..

作为一名训练有素的神经外科医生，曼西博士熟悉患者在需要时获得治疗所面临的挑战。受到一名成功接受脑部手术但因手术太迟而死亡的患者的启发，Mansi博士于2016年成立了Viz.ai，目标是利用人工智能加速护理协调，减少患者与救生治疗之间的系统性延误。。

“Chris's unwavering commitment to increasing patient access to life-saving treatments is deserving of this recognition,” said Mamoon Hamid, Partner, Kleiner Perkins. “The significance of the Viz.ai team's impact cannot be overstated. They are getting patients to the right diagnosis, specialist, and treatment faster, ensuring that they don’t get lost in our complex healthcare system.”.

“克里斯坚定不移地致力于增加患者获得救生治疗的机会，这值得我们的认可，”克莱纳·珀金斯（Kleiner Perkins）合伙人马穆恩·哈米德（Mamoon Hamid）说。“Viz.ai团队的影响意义不可小觑。他们正在让患者更快地得到正确的诊断、专家和治疗，确保他们不会在我们复杂的医疗体系中迷失方向。”。

With two de Novo clearances by the Food and Drug Administration (FDA) since 2018 and more than 50,000 providers today across 1700 hospitals on the end-to-end platform, Viz.ai continues to lead transformation in healthcare and life sciences and provide real-world impacts for patients.

自2018年以来，美国食品和药物管理局（FDA）进行了两次从头批准，如今1700家医院的端到端平台上有超过50000家供应商，Viz.ai继续引领医疗保健和生命科学的变革，并为患者提供现实世界的影响。

The TIME100 AI list is an annual global recognition that features remarkable leaders, scientists, policymakers, and entrepreneurs across various fields who are shaping today's AI landscape. To assemble the list, TIME's editors and reporters solicited nominations and recommendations from industry leaders and dozens of expert sources.

《时代100》人工智能排行榜是一项年度全球认可活动，其中包括塑造当今人工智能格局的各个领域的杰出领导者、科学家、决策者和企业家。为了收集这份名单，时代周刊的编辑和记者征求了行业领袖和数十位专家的提名和建议。

The TIME100 AI list will be featured in the September 16, 2024 issue of TIME, available on newsstands beginning Friday, September 6..

TIME100 AI列表将在2024年9月16日的《时代》杂志上发布，从9月6日（星期五）开始在报摊上发售。。

About Viz.ai, Inc.

关于Viz.ai，Inc。

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes.

Viz.ai是使用ai算法和机器学习提高美国和欧洲1700家医院和卫生系统诊断和护理速度的先驱。人工智能支持的Viz.AI OneTM是一种智能护理协调解决方案，可识别更多疑似疾病患者，在护理点告知关键决策，优化护理途径并帮助改善结果。

Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai..

在现实世界的临床证据的支持下，Viz.ai One为患者，提供者以及制药和医疗器械公司提供了巨大的价值。有关更多信息，请访问viz。ai。。